Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Fosamax by Year
Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)
Merck Fosamax: $209M in FY2018, down 13.3% from a year earlier. No newer figure appears in the documents we track.
Where the FY2018 figure comes from
“|| Fosamax | 209 | 241 | -13 | 4 | 6 | -33 | 205 | 235 | -13”
Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | 209 | -13.3% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 241 | -15.1% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 284 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up fosamax
- Fosamax (alendronate, legacy pre-Organon spin-off) — U.S. sales ($M)4 · FY2018
- Fosamax (alendronate, legacy pre-Organon spin-off) — International sales ($M)205 · FY2018
- Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%)-13.0% · FY2018
- Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide constant-currency (ex-exchange) growth YoY (%)-15.0% · FY2018
Cite this data
StockData. (2026). Merck Fosamax ($M), annual FY2016–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-fosamax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.